Mon. 25 Mar 2024, 7:36am ET
Benzinga
Biotech, News, Health Care, General
- Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects
- AnnAraC has potential to fill significant unmet need and expected to increase 2nd line AML CRs more than double over existing 2nd line therapies
- All 82 Annamycin subjects (in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy
- Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway